Recent advancement in drug development of nitro(NO2)‐heterocyclic compounds as lead scaffolds for the treatment of Mycobacterium tuberculosis

Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis (Mtb). It was responsible for approximately 1.4 million deaths worldwide in 2019. The lack of new drugs to treat drug‐resistant strains is a principal factor for the slow rise in TB infections. Our aim is t...

Full description

Saved in:
Bibliographic Details
Published in:Drug development research 2022-06, Vol.83 (4), p.842-858
Main Authors: Scarim, Cauê Benito, Pavan, Fernando Rogério
Format: Article
Language:English
Subjects:
antimycobacterial
Drug development
H37Rv strain
Heterocyclic compounds
Infectious diseases
minimum inhibitory concentrations
Mycobacterium tuberculosis
new drugs
nitro compounds
Nitrogen dioxide
Tuberculosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis (Mtb). It was responsible for approximately 1.4 million deaths worldwide in 2019. The lack of new drugs to treat drug‐resistant strains is a principal factor for the slow rise in TB infections. Our aim is to aid the development of new TB treatments by describing improvements (last decade, 2011–2021) to nitro(NO2)‐based compounds that have shown activity or pharmacological properties (e.g., anti‐proliferative, anti‐kinetoplastid) against Mtb. For all compounds, we have included final correlations of minimum inhibitory concentrations against Mtb (H37Rv).
ISSN:0272-4391
1098-2299
DOI:10.1002/ddr.21921